Browsed by
Month: April 2022

Fast Track Designation for Rockville’s ICT

Fast Track Designation for Rockville’s ICT

ROCKVILLE, MARYLAND, April 19, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GCC19CART, the Company’s lead solid tumor therapy candidate in treating patients with relapsed and refractory metastatic colorectal cancer R/R mCRC. ...  Read more

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-CELL Therapy Manufacturing Facility in Maryland

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-CELL Therapy Manufacturing Facility in Maryland

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies

Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation

SANTA MONICA, Calif.–(BUSINESS WIRE)–April 19, 2022– Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer. ...  Read more